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Abstract
Background and purpose
Central adjudication of serious adverse events (SAEs) can be undertaken in clinical trials,
especially for open-label studies where outcome assessment may be at risk of bias. This
study explored the effect of central adjudication of SAEs on the safety results of the Efficacy
of Nitric Oxide in Stroke (ENOS) Trial.
Methods
ENOS assigned patients with acute stroke at random to receive either transdermal glyceryl
trinitrate (GTN) or no GTN and to Stop or Continue previous antihypertensive treatment.
SAEs were reported by local investigators who were not blinded to treatment allocation.
Central adjudicators, blinded to treatment allocation, reviewed the investigators reports and
used evidence available to confirm or re-categorise the classification of event, likely causal-
ity, diagnosis and expectedness of event.
Results
Of 4011 patients enrolled in ENOS, 1473 SAEs were reported by local investigators; this
was reduced to 1444 after the review by adjudicators, with 29 re-classified as not an SAE.
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There was fair agreement between investigators and adjudicators regarding likely causality,
with 808 agreements and 644 disagreements (56% crude agreement, weighted kappa, κ =
0.31). Agreement increased upon dichotomisation of the causality categories, with 1432
agreements and 20 disagreements (99% crude agreement, kappa = 0.54). Repeating the
main trial safety analysis with investigator reported events showed that adjudication had no
effect on the main trial safety conclusions.
Conclusions
In a large trial, with many SAEs reported, central adjudication of these events did not affect
trial conclusions. This suggests that adjudication of SAEs in a clinical trial where the inter-
vention already has a well-established safety profile may not be necessary. Potential effi-
ciency savings (financial, logistical) can be made through not adjudicating SAEs.
Introduction
In clinical trials, the side-effects or hazards of an intervention must be measured alongside the
potential benefits. Therefore, it is important that clinical trials collect high-quality data on the
safety of an intervention as well as its potential efficacy. To ensure that data collected is reliable
and robust, many clinical trials use a central adjudication process. This involves one or more
experts who re-evaluate trial data, blinded to treatment assignment, to assess events reported
by the local site assessors and decide whether or not they agree, or to categorise them in a spe-
cific way. Central adjudication is thought to improve the classification of events, therefore
reducing noise and helping to improve accuracy and precision of effect estimates[1, 2]. For
open-label studies, adjudication is also thought to help protect against detection bias, as adju-
dicators are blinded to treatment allocation (and patient characteristics) whenever possible[3].
It has been shown that unblinded local assessors often exaggerate effect estimates[4, 5]. FDA
and EMA guidelines suggest that adjudication is particularly valuable ‘when the intervention is
not delivered in a blinded fashion’ [6] or when ‘endpoints are complex to assess and/or include
subjective components’[7].
The use of central adjudication in clinical trials has become commonplace in many clinical
areas[8]. For example, over 80% of trials in cardiovascular disease are reported to include adju-
dication[9]. Both the FDA and EMA have published guidelines which advocate the need for an
adjudication committee to assess cardiovascular outcomes in diabetes phase 2 and 3 trials[10,
11]. Cardiovascular safety outcomes are regularly adjudicated, with central adjudication often
used to determine cause of death[12–14] and adverse events such as bleeding[15]. In an ortho-
paedic trial, self-reported cardiovascular serious adverse events such as stroke and myocardial
infarction were adjudicated[16]. The study found that adjudication was vital to the trial results
and interpretation, with only 58% of self-reported strokes verified by adjudicators. However,
in a large stroke trial where adjudicators assessed cause of death, there was excellent agreement
between adjudicators and local site investigators, with agreement being 94% and 93% for car-
diovascular and cancer death respectively[14].
There is a current drive to reduce research waste in clinical trials, particularly through the
REWARD campaign, which lists regulation and management[17] and efficient design, con-
duct and analysis[18] as areas to be addressed, as well as specifically targeting stroke research
as an area to reduce waste through the European Stroke Organisation Trials Network
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Committee[19]. The campaign recommends that we ‘streamline and harmonise the laws, regu-
lations, guidelines . . . and ensure that they are proportionate to the plausible risks associated
with the research’ and calls for ‘additional research to learn how efficiency can be
increased’[17]. Furthermore the campaign aims to “identify sources of waste in the way stroke
research is chosen, designed, conducted, analysed, regulated, managed, disseminated, and
reported”[19]. Given that adjudication of cardiovascular safety outcomes can be a burden to
both the trial and site teams, taking considerable time and valuable resources to implement, it
is important to assess the usefulness of this process.
The aim of this secondary analysis was to investigate the effect of central adjudication of
serious adverse events (SAEs) on a large international stroke trial. The two objectives were to:
(1) describe the level of agreement between central adjudicators and local investigators; (2)
assess the effect of central adjudication of SAEs on the primary safety analysis of the trial.
Methods
Efficacy of Nitric Oxide in Stroke (ENOS) trial
The Efficacy of Nitric Oxide in Stroke (ENOS) trial was an international prospective rando-
mised single-blind masked-endpoint partial-factorial trial that compared transdermal glyceryl
trinitrate (GTN) with no GTN in patients with acute stroke and raised blood pressure[20]. A
subset of patients who were already taking anti-hypertensive medication before entry into the
trial were further assigned at random to continue or stop their medication. The trial recruited
4011 patients from 173 sites, across 23 countries on five continents between 2001 and 2013.
The primary safety analysis found that there was no evidence to suggest the proportion of
patients with SAEs differed between treatment groups. The protocol, statistical analysis plan,
and main results for ENOS are described in detail elsewhere[20–22]. The clinical trial registra-
tion for ENOS is given on http://www.clinicaltrials.gov (Unique identifier: NCT00989716).
Adjudication of investigator reported serious adverse events
Serious adverse events were defined in the protocol as adverse events that: were fatal, caused
disability, were life threatening, led to hospital admission or prolonged discharge in a hospital-
ised patient, and/or resulted in birth defects in children born to trial participants. Excepting a
small number of selected adverse events (such as headache), which were recorded but not
adjudicated, non-serious adverse events were not recorded due to the established nature of the
trial interventions. SAEs were recorded by local investigators using a web-based SAE form
within 24 hours of the investigator being aware of the event. Local investigators were trained
in SAE reporting before site initiation. Once five participants had been recruited by any partic-
ipating trial site, there was a further site visit and ongoing data monitoring. Additional training
was provided in yearly investigator meetings and regular trial newsletters also included hints
and tips as well as frequently answered questions for SAE reporting.
It was not possible to blind local investigators to treatment allocation as they knew whether
patients had received the GTN patch or not, and if patients were randomised to continue or
stop their anti-hypertensive medication. The local investigator report included event classifica-
tion, event diagnosis and evidence used to determine diagnosis, expectedness of event, and
likely causality. Likely causality was reported in five categories: Definitely not, Unlikely (to be),
Possibly, Probably and Definitely related to treatment.
Two central independent expert assessors, referred to throughout this article as adjudica-
tors, who were blinded to treatment allocation, evaluated the investigator-reported SAEs. Each
event was reviewed by a single adjudicator. The independent adjudicators had access to the
web-based SAE form provided by the local investigator, a list of known adverse reactions and
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evidence provided by investigators including clinical notes, cranial scans, biochemistry and
bacteriology data. Adjudicators were able to request further information from the specific trial
sites if this was required to carry out the assessment of the SAE. Adjudicators confirmed or re-
categorised investigators’ decisions on classification of event, event diagnosis, expectedness of
event and likely causality. Any uncertainty was clarified by discussion with the chief investiga-
tor blinded to treatment allocation. The central adjudicator’s decision was treated as the gold
standard for this study and was the decision used in all ENOS trial analyses.
Statistical methods
Continuous variables were summarised using mean and standard deviation, or median and
interquartile range. Categorical variables were described using number (%). Mann-Whitney u
tests and Chi-square tests were used to determine imbalance between treatment groups for
investigator reported SAEs. We used unweighted kappa to estimate agreement between local
investigators and central adjudicators on event classification and diagnosis. Agreement
between local investigators and central adjudicators on likely causality of SAEs was calculated
using weighted kappa with symmetric weights. Weights were assigned as 1 if adjudicators and
investigators agreed, as 0.75 if adjudicators and investigators causalities differed by one, as 0.5
if adjudicators and investigators causalities differed by two and 0 if adjudicators and investiga-
tors causalities differed by more than two. The likely causality categories were dichotomised
into Definitely not, Unlikely and Possibly versus Probably and Definitely, with kappa used to
estimate agreement. The number of patients with any SAE and the number of patients for each
SAE diagnosis were compared by treatment arm using chi-squared tests for both local-investi-
gator- and central-adjudicator-reported events. The time taken to adjudicate SAEs was esti-
mated as the difference between the time the adjudicator first assessed the event and the time
the event was completed. All analyses were performed in Stata version 14.0 or later.
Results
Of 4011 patients enrolled into ENOS, 1031 (26%) were recorded as having had at least one
SAE by local investigators. In total, local investigators reported 1473 SAEs, and of these, 1444
(98%) were classified as an SAE after assessment by central adjudicators.
The number of SAEs were similar between the GTN versus No GTN arms. Events were
more likely to be moderate or mild than severe if a patient had been randomised to receive the
GTN patch (Table 1). Investigators used clinical diagnostic evidence for roughly three-quarters
of the SAEs (74%), with radiological (47%), biochemical (30%), haematological (26%) and
ECG (23%) diagnostic evidence also used regularly. Adjudicators were certain of SAE diagno-
sis for the majority of investigator-reported events (76%), but indicated that their diagnosis
was only possibly correct for 68 (5%) of the 1473 investigator-reported SAEs.
Agreement was excellent between central adjudicators and local investigators for the diag-
nosis of SAEs (Fig 1, see Supporting Information, S1 Table, crude agreement = 88%,
unweighted kappa κ = 0.85). The highest number of disagreements, ignoring the miscella-
neous category, was seen between cardiovascular events (25/337, 7%) and respiratory events
(35/294, 12%). Genito-urinary SAEs had one of the largest percent disagreements for any cate-
gory with over 20 events, with adjudicators disagreeing with investigators on 14/104 occasions
(13%).
Within the cardiovascular category, there was excellent agreement (337 events, crude agree-
ment = 84%, unweighted kappa, κ = 0.82). Agreement within the central nervous system was
good (420 events, crude agreement = 76%, unweighted kappa, κ = 0.72). Within this category,
investigators identified 57 (79%) of the 72 complication of initial stroke events, 75 (87%) of the
Adjudication of serious adverse events in ENOS
PLOS ONE | https://doi.org/10.1371/journal.pone.0208142 November 26, 2018 4 / 12
86 recurrent stroke events and 74 (73%) of the 102 extension of initial stroke events. A large
number of the incorrectly identified events for these three sub-categories should have been
classified in one of the other two sub-categories. For complication, recurrence and extension
this crossover was 47%, 82% and 82% respectively. Agreement was only fair within the
Table 1. Characteristics of investigator reported serious adverse events and certainty of adjudicator’s diagnosis.
All GTN No GTN p
Patients 4011 2000 2011
With SAE 1031 522 509
SAEs 1473 781 692
SAEs per patient
Mean (SD) 1.5 (1.0) 1.6 (1.1) 1.4 (0.8) 0.063�
Median [IQR] 1 [1, 2] 1 [1, 2] 1 [1, 2]
Min, Max 1, 9 1, 9 1, 6
Timing of event
Before treatment 14 (1%) 6 (1%) 8 (1%) 0.61†
During treatment 642 (44%) 335 (43%) 307 (44%)
After treatment 817 (55%) 440 (56%) 377 (54%)
Time from randomisation to event (days)
Mean (SD) 22.5 (27.1) 22.7 (28.6) 22.1 (25.5) 0.97�
Median [IQR] 11 [3, 34] 12 [3, 33] 10 [4, 36]
Min, Max 0, 383 0, 383 0, 148
Diagnostic evidence used by investigators‡
Pathological 94 (6%) 45 (6%) 49 (7%) 0.74†
Radiological 685 (47%) 376 (48%) 309 (45%)
ECG 336 (23%) 178 (23%) 158 (23%)
Bacteriology 168 (11%) 93 (12%) 75 (11%)
Biochemistry 443 (30%) 232 (30%) 211 (30%)
Haematology 383 (26%) 201 (26%) 182 (26%)
Clinical 1095 (74%) 593 (76%) 502 (73%)
Other 234 (16%) 115 (15%) 119 (17%)
Intensity of event
Mild 214 (15%) 133 (17%) 81 (12%) 0.003†
Moderate 448 (30%) 246 (31%) 202 (29%)
Severe 810 (55%) 402 (51%) 408 (69%)
Clinical outcome
Recovered 479 (33%) 268 (34%) 211 (30%) 0.006†
Not yet recovered 542 (37%) 302 (39%) 240 (35%)
Died 451 (31%) 211 (27%) 240 (35%)
Certainty of adjudicators event diagnosis
Definite 1126 (76%) 593 (76%) 533 (77%) 0.062†
Probable 276 (19%) 153 (20%) 123 (18%)
Possible 68 (5%) 34 (4%) 34 (5%)
All data is N(%) unless otherwise indicated
GTN = Glyceryl trinitrate
�p-value from Mann-Whitney u test
†p-value from chi-square test
‡Categories not mutually exclusive
https://doi.org/10.1371/journal.pone.0208142.t001
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respiratory category (294 events, crude agreement = 73%, unweighted kappa, κ = 0.35), with
only 192 of the 262 pneumonia events identified by investigators. 16 of these events were
incorrectly classified as complication of initial stroke and 37 were classified by investigators as
a chest infection.
There was fair agreement on likely causality of SAEs between central adjudicators and local
investigators, with disagreement for 644/1452 (44%) events (Table 2, weighted kappa, κ =
0.31). When categories were dichotomised into Definitely not/Unlikely/Possibly versus Proba-
bly/Definitely there was near perfect agreement (Table 3, crude agreement = 99%, kappa κ =
0.54). If categories instead were dichotomised into Definitely not/Unlikely versus Possibly/
Probably/Definitely, then crude agreement remained high, but agreement over that expected
by chance was reduced (crude agreement = 90%, kappa κ = 0.33).
Central adjudication of SAEs had little impact compared with site investigators on the
number of patients with any SAE reported for both the GTN vs No GTN and Continue vs
Stop comparisons (Table 4). There were small differences between investigator- and adjudica-
tor-reported SAEs for each SAE diagnosis, with evidence of a between-group effect differing
Fig 1. Agreement on serious adverse event diagnosis between central adjudicators and local investigators.
https://doi.org/10.1371/journal.pone.0208142.g001
Table 2. Agreement on likely causality of serious adverse events between central adjudicators and local investigators.
Central Adjudicators
Local Investigators Definitely not Unlikely Possibly Probably Definitely Total
Definitely not 558 154 28 0 0 740
Unlikely 325 223 47 1 0 596
Possibly 20 46 19 4 0 89
Probably 1 4 8 5 0 18
Definitely 0 0 2 4 3 9
Total 904 427 104 14 3 1452
Disagreements (%) 346 (38%) 204 (48%) 85 (82%) 9 (64%) 0 (0%) 644 (44%)
Crude agreement = 808/1452 = 56%
Weighted kappa = 0.31 (0.27, 0.35), Unweighted kappa = 0.20 (0.16, 0.24)
21 events did not have relatedness of treatment to SAE recorded by either adjudicators or investigators (Central Adjudicators = 19, Local Investigators = 2) and so were
not included in this analysis
https://doi.org/10.1371/journal.pone.0208142.t002
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for extension of initial stroke and recurrent stroke (both GTN vs No GTN comparison). Inves-
tigators poorly identified complication of initial stroke, with 57 events classified that were not
confirmed by adjudicators (see Supporting information, S2 Table).
Of the 1473 SAEs reported by local investigators, 15 had missing information for time of
event completion. From the SAEs with complete data, 1297 (88%) were completed by adjudi-
cators within 24 hours. 127 (9%) events took at least 90 days for the adjudication to be com-
pleted as they required further information that was not readily available.
Discussion
Our study investigated the usefulness of central SAE adjudication in a large stroke trial with a
single-blind design, hence local assessors were unbilnded to treatment allocation. We found
that agreement between central adjudicators and local investigators was excellent for the diag-
nosis of events. However, there was worse agreement on likely causality of SAEs when assessed
on a 5-point scale, although this improved substantially when categories were dichotomised.
Overall, adjudication of SAEs had no impact on the primary safety results of ENOS, with a
similar number of adjudicator-reported and investigator-reported SAEs reported.
Other studies have also reported that central adjudication has no effect on the primary
safety results [15, 23]. However, one of these studies found that adjudication of specific SAE
diagnoses (debilitating stroke, refractory angina, new heart failure) did alter the significance of
these outcomes[23]. All of these diagnoses could be considered ’softer’ outcomes and rely on
clinical factors and opinion rather than diagnostic tests and reports. These results are in agree-
ment with our findings, which indicate that adjudication of SAEs has the potential to impact
on the safety results of specific SAE diagnoses, in this case recurrent stroke and extension of
initial stroke. However, caution should be taken with this result as in our study the number of
events reported are low, the number of hypothesis tests conducted are high, and the actual
number of events did not change dramatically in either case. In ENOS, adjudicators referred
strictly to the protocol definitions for SAEs, whereas local investigators may not have followed
these so rigorously, which could explain in part this finding. One potential approach for future
studies could be to adjudicate a subset of events which are known to be difficult to diagnose,
reducing the amount of adjudication needed whilst still ensuring the events with the highest
chance of misclassification are adjudicated.
Furthermore, adjudication could be applied selectively, concentrating on major safety out-
comes rather than all SAEs. Many trials, especially academically run, test treatments which
already have a well-established safety profile, for which important safety issues can be pre-
dicted[24]. Therefore, relevant safety events can be listed at the trial design stage, and these can
Table 3. Agreement on likely causality of SAEs between central adjudicators and local investigators–dichotomous analysis.
Central Adjudicators
Local Investigators Definitely not, Unlikely or Possibly Probably or Definitely Total
Definitely not, Unlikely or Possibly 1420 5 1425
Probably or Definitely 15 12 27
Total 1435 17 1452
Disagreements (%) 15 (1%) 5 (29%) 20 (1%)
Crude agreement = 1432/1452 = 99%
Unweighted kappa = 0.54 (0.49, 0.24)
21 events did not have relatedness of treatment to SAE recorded by either adjudicators or investigators (Central Adjudicators = 19, Local Investigators = 2) and so were
not included in this analysis
https://doi.org/10.1371/journal.pone.0208142.t003
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be chosen to be adjudicated, which would allow the number of events for adjudication to be
greatly restricted and increase the chance that adjudication could be shown to impact mean-
ingfully on the interpretation, since it limits the dilution of less relevant SAE ‘noise’.
We found reasonable agreement between adjudicators and investigators for likely causality
of SAEs. Investigators were more likely to report that SAEs were related to treatment than cen-
tral adjudicators. After dichotomisation, events could be categorised as serious adverse reac-
tions (SARs) which would be SAEs rated as probably or definitely related to treatment. In this
case, agreement increased to 99%, and there would have been few SAEs that would have been
incorrectly categorised as serious adverse reactions (SARs) and vice versa. This implies that
Table 4. Number of patients with serious adverse events during follow-up at day 90 classified by local investigators and central adjudicators: GTN vs no GTN and
continue vs stop.
GTN (n = 2000) No GTN (n = 2011) p-value� Continue (n = 1053) Stop (n = 1044) p-value�
Any SAE
Local Investigator 522 509 0.57 312 297 0.55
Central Adjudicator 520 502 0.45 310 294 0.52
Complication of initial stroke
Local Investigator 67 53 0.18 26 36 0.19
Central Adjudicator 40 31 0.27 19 16 0.63
Extension of initial stroke
Local Investigator 50 37 0.15 32 23 0.23
Central Adjudicator 59 37 0.021 33 23 0.19
Symptomatic intracranial haemorrhage
Local Investigator 23 19 0.52 10 18 0.12
Central Adjudicator 27 17 0.13 11 16 0.32
Recurrent stroke
Local Investigator 57 32 0.007 29 27 0.81
Central Adjudicator 47 35 0.17 25 27 0.80
Myocardial infarction
Local Investigator 18 25 0.29 9 18 0.077
Central Adjudicator 19 22 0.65 11 16 0.32
Sudden cardiac death
Local Investigator 3 5 0.48 1 3 0.31
Central Adjudicator 6 6 0.99 1 5 0.10
Other cardiovascular event
Local Investigator 119 103 0.25 64 72 0.45
Central Adjudicator 109 97 0.37 60 66 0.55
Pulmonary embolism
Local Investigator 26 17 0.16 10 11 0.81
Central Adjudicator 26 19 0.29 11 13 0.70
Pneumonia
Local Investigator 89 100 0.44 74 50 0.030
Central Adjudicator 117 122 0.77 88 63 0.040
Other event
Local Investigator 210 220 0.65 140 115 0.11
Central Adjudicator 212 212 0.95 134 119 0.35
�p-values are from a chi-squared test between treatment groups
GTN = Glyceryl trinitrate
https://doi.org/10.1371/journal.pone.0208142.t004
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even though agreement on likely causality was not high, the disagreements were confined to
the related/not related to treatment categories, and there was minimal crossover, suggesting
adjudication of SAEs may not be needed to ensure SAEs and SARs are categorised properly.
We found that the highest number of disagreements between adjudicators and investigators
was for the Possibly category. Whilst assessing causality is subjective, the Possibly category is
arguably the most subjective, and we propose that this category is currently unhelpful and not
well understood. Furthermore, it could be argued that adjudicating causality is not relevant,
given that safety reporting for serious adverse events in trials is required within a short pre-
specified timeframe. Adjudication often takes place some weeks after the original event, and it
is often the case that causality is not permitted to be downgraded, thus adjudication of causal-
ity has a limited impact in trials.
Whilst adjudication in trials may improve the accuracy of findings, the process comes at a
considerable cost. We found that adjudicators required more information than that provided
by investigators in 161 of the events they assessed, and this information took substantial time
to obtain, in some cases with the adjudicators having to re-request data multiple times. Whilst
only a portion of the time we estimated would have actually been used to adjudicate SAEs, this
highlights the sizeable task of implementing adjudication in clinical trials. This burden is
shared between central trial and site teams, and must be funded appropriately. In a thrombo-
prophylaxis trial, adjudication was estimated to cost $75 per adjudicated event[25]. Therefore,
using this as a rough guide due to similarities in adjudication methods, we could assume that
adjudication of SAEs in ENOS may have cost in the region of $110,000. This amount is not
insignificant, and, if adjudication of SAEs continues to be prescribed as best practice, or even a
necessity for trials that investigate cardiovascular outcomes, then the cost of such a process
needs to be properly evaluated against the benefits that it actually brings to a trial.
A strength of this study is that we had data on nearly 1500 SAEs from a large, well con-
ducted randomised trial to use in our analysis. As well as this, the amount of missing data was
low, with a high level of data completeness for both adjudicator- and investigator-assessed
events. This study was designed and undertaken once the ENOS trial had finished, and so it
was not possible that the presence of this study had any influence on investigators’ or adjudica-
tors’ behaviour. One limitation of this study was that there was no quality control measure due
to each SAE only being assessed by a single adjudicator. Whilst this meant the process used
less resources, there was also a higher chance of random error[26], but level of agreement sug-
gests this wasn’t an issue in ENOS. Additionally, in ENOS, only events reported by investiga-
tors were adjudicated. Thus, after adjudication, the total number of SAEs could either stay the
same, or decrease. This approach could potentially miss SAEs that were not identified by inves-
tigators during the trial. In fact, as investigators were not blinded to treatment allocation, there
was the potential for SAEs to be selectively reported. Granger et al.[1] suggests a potential alter-
native, where adjudicators also review “events that are ‘triggered’ by some feature that raises
the suspicion of an event”. This method has been carried out previously, with computer algo-
rithms used to identify events to adjudicate[8].
In summary, this study found that local site investigators could accurately determine SAE
diagnosis in a large international trial. Adjudication of investigator-reported SAEs had no
impact on the main trial safety conclusions. The purpose of SAE adjudication in a large trial,
where the intervention already has a well-established safety profile, needs to be considered
before implementing a potentially expensive and time-consuming process. Further research
should provide an accurate evaluation of the cost and time involved in adjudication to better
understand how useful the process is for clinical trials.
Adjudication of serious adverse events in ENOS
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